Skip to content
Peptide research

Survodutide

Also known as BI 456906
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

Survodutide is a dual glucagon/GLP-1 receptor agonist marketed for weight loss, blood sugar control, and liver fat reduction in MASH. Evidence is human and fairly strong, though cardiovascular benefit is speculative. The main concern is tolerability: nausea and vomiting occur several times more than placebo, driving high discontinuation; long-term cardiovascular safety is unproven. It is not FDA-approved, so supply falls outside standard channels.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Survodutide (BI 456906) is an investigational peptide developed by Boehringer Ingelheim that activates two hormone receptors simultaneously: the glucagon receptor and the GLP-1 receptor. It is a modified version of glucagon engineered to also activate GLP-1 signaling, combining appetite suppression (from the GLP-1 side) with increased fat burning and energy expenditure (from the glucagon side). It is being developed for obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis, formerly known as fatty liver disease) and is currently in Phase 3 clinical trials.

How it works in the body

A dual glucagon and GLP-1 receptor agonist. The glucagon component increases energy expenditure and promotes fat breakdown in the liver (important for fatty liver disease). The GLP-1 component suppresses appetite and improves blood sugar control. Together they address obesity from both the intake and expenditure sides.

Research overview

Survodutide works through two complementary pathways: GLP-1 receptor activation suppresses appetite, slows stomach emptying, and helps regulate insulin, while glucagon receptor activation stimulates the liver to burn fat, increases overall energy expenditure, and directly reduces liver fat content. In Phase 2 trials, the highest dose (4.8 mg weekly) produced an average 18.7% body weight loss over 46 weeks. Participants were 3.4 times more likely to lose at least 5% of their body weight and 5.9 times more likely to lose at least 10% compared to placebo. The liver disease results were particularly striking: in the MASH Phase 2 trial (published in the New England Journal of Medicine, 2024), 62% of participants in the 4.8 mg group achieved improvement in liver disease without worsening of scarring, versus just 14% on placebo. Phase 3 development includes the SYNCHRONIZE obesity program and the LIVERAGE MASH program. Phase 3 obesity and liver-fat results have been published; survodutide remains unapproved.

Who researches Survodutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk.

  • Those with History of pancreatitis

    High

    GLP-1 class effect on pancreatitis risk. Monitor closely.

  • Those with Severe gastroparesis

    High

    GLP-1 component slows gastric emptying.

  • Those who are pregnant or breastfeeding

    Absolute

    Investigational — no safety data.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk.

  • History of pancreatitis

    High

    GLP-1 class effect on pancreatitis risk. Monitor closely.

  • Severe gastroparesis

    High

    GLP-1 component slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Investigational — no safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(10)

Rated by level of concern

  • Gastrointestinal adverse events: nausea (3.3x placebo risk), vomiting (6.64x), diarrhea (1.89x), dyspepsia (6.93x), early satiety (6.44x)

    High

    PMID 38847460 (NEJM 2024, phase 2 MASH); PMID 40557198 (Proc Bayl Univ Med Cent 2025 meta-analysis, diarrhea RR 1.89); PMID 42253238 (NEJM 2026, phase 3). Treat exact ratios as approximate.

  • Higher treatment discontinuation rate due to adverse events (RR 4.53 vs placebo)

    High

    PMID 38330987 (Lancet Diabetes Endocrinol 2024); PMID 40688625 (Indian J Endocrinol Metab 2025 meta-analysis). The RR 4.53 figure is approximate.

  • Mild increase in heart rate (mean 2.7 bpm increase vs 0.1 bpm for placebo)

    Moderate

    PMID 38330987 (Lancet Diabetes Endocrinol 2024, for direction); NCT06200467 (phase 1 cardiac safety study, completed October 2025 per ClinicalTrials.gov, October 2026). The exact bpm figures are approximate.

  • Dose-dependent GI tolerability — higher doses may cause more pronounced nausea and vomiting

    High

    PMID 38095657 (Diabetologia 2024); PMID 42253238 (NEJM 2026, phase 3).

  • Long-term cardiovascular safety not yet established (the SYNCHRONIZE-CVOT trial, NCT06077864, completed in June 2026; no outcome results in the cited literature)

    Moderate

    No published survodutide CV outcome data in the cited literature; NCT06077864 completed June 2026 (per ClinicalTrials.gov, October 2026).

  • Potential for hypoglycemia when combined with insulin or sulfonylureas (theoretical risk based on GLP-1R agonist class)

    Moderate

    GLP-1 receptor agonist class labeling; PMID 38095657 (Diabetologia 2024, T2D phase 2).

  • Published phase 3 obesity data extend to 76 weeks; longer-term safety remains under study.

    Moderate

    PMID 38330987 (46-week phase 2) and PMID 38847460 (48-week phase 2); PMID 42253238 (76-week phase 3, NEJM 2026); NCT06077864 (phase 3 cardiovascular safety trial, completed June 2026 per ClinicalTrials.gov, October 2026).

  • Injection site reactions possible with subcutaneous administration

    Low

    PMID 38330987 (Lancet Diabetes Endocrinol 2024).

  • Weight regain upon discontinuation not yet characterized

    Moderate

    Incretin class randomized-withdrawal evidence (class-level). No survodutide-specific withdrawal trial identified.

  • Safety in patients with severe renal or hepatic impairment not fully established

    Low

    PMID 38857788 (J Hepatol 2024, cirrhosis); NCT06352411 (phase 1 renal-impairment study, completed September 2025) and NCT06632457 (phase 3 MASH cirrhosis trial, recruiting), per ClinicalTrials.gov, October 2026.

Interaction summary(8)

Rated by direction with this peptide

  • Insulin (basal or prandial)

    CautionModerate

    Adding a GLP-1 receptor agonist to insulin substantially raises hypoglycemia risk and background insulin doses generally need proactive reduction, even though survodutide's glucagon component partially offsets glucose lowering.

    GLP-1 receptor agonist class labeling; PMID 38095657 (Diabetologia 2024).

  • Sulfonylureas (glipizide, glimepiride, glyburide)

    CautionModerate

    Sulfonylureas drive glucose-independent insulin secretion, so combining them with survodutide's incretin effect and appetite suppression creates a real hypoglycemia risk usually calling for sulfonylurea dose reduction or discontinuation. Well-established class effect.

    GLP-1 receptor agonist class labeling; PMID 38095657 (Diabetologia 2024).

  • Narrow-therapeutic-index oral drugs (levothyroxine, warfarin, oral contraceptives, immunosuppressants)

    CautionLow

    Delayed gastric emptying can alter the rate/extent of oral absorption, so tight-therapeutic-window drugs warrant monitoring during dose escalation. Mechanism-based, rated Low. A dedicated interaction study with midazolam, caffeine and bupropion probes (NCT06564441) completed in January 2026; no results are in the cited literature.

    GLP-1 class gastric-emptying pharmacology; NCT06564441 (phase 1 interaction study, completed January 2026, per ClinicalTrials.gov, October 2026).

  • Anesthesia and procedural sedation (elective surgery, endoscopy)

    CautionModerate

    Retained gastric contents from delayed emptying raise pulmonary aspiration risk under sedation; anesthesiology society guidance for the GLP-1 class recommends holding weekly agents before elective procedures, and survodutide should be assumed to carry the same requirement. Reasonable class-level extension.

    American Society of Anesthesiologists GLP-1 receptor agonist perioperative guidance (class-level).

  • Other GLP-1 or incretin agonists (semaglutide, tirzepatide, liraglutide)

    CautionModerate

    Concurrent use is pharmacologically redundant at the GLP-1 receptor and adds GI toxicity without established efficacy gain; the phase 2 program compared survodutide against semaglutide rather than using them together.

    PMID 38095657 (Diabetologia 2024, open-label semaglutide comparator arm).

  • Metformin

    NeutralLow

    Metformin was common background therapy in the survodutide diabetes trials with no signal of pharmacokinetic interaction or added hypoglycemia; mechanisms are complementary. Neutral is correct.

    PMID 38095657 (Diabetologia 2024).

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Non-overlapping mechanisms give additive glycemic and weight effects with low intrinsic hypoglycemia risk; combined osmotic diuresis and GI fluid losses make volume depletion the practical thing to watch.

    Mechanism-based; GLP-1/SGLT2 combination evidence in type 2 diabetes (class-level).

  • Alcohol

    CautionTheoretical

    In patients treated for steatotic liver disease, alcohol counteracts hepatic benefit and may compound nausea; no survodutide-specific interaction data exist. Rated Theoretical.

    Mechanism-based; no survodutide-specific study.

Known risks(10)

  • Gastrointestinal adverse events: nausea (3.3x placebo risk), vomiting (6.64x), diarrhea (1.89x), dyspepsia (6.93x), early satiety (6.44x)

  • Higher treatment discontinuation rate due to adverse events (RR 4.53 vs placebo)

  • Mild increase in heart rate (mean 2.7 bpm increase vs 0.1 bpm for placebo)

  • Dose-dependent GI tolerability — higher doses may cause more pronounced nausea and vomiting

  • Long-term cardiovascular safety not yet established (SYNCHRONIZE-CVOT trial ongoing)

  • Potential for hypoglycemia when combined with insulin or sulfonylureas (theoretical risk based on GLP-1R agonist class)

  • Published phase 3 obesity data extend to 76 weeks; longer-term safety remains under study.

  • Injection site reactions possible with subcutaneous administration

  • Weight regain upon discontinuation not yet characterized

  • Safety in patients with severe renal or hepatic impairment not fully established

Drug interactions(5)

  • Metformin

    Co-administered in clinical trials without apparent adverse interaction; no adjustment reported necessary.

  • Insulin and insulin secretagogues

    Theoretical increased risk of hypoglycemia due to GLP-1R agonism enhancing insulin secretion; dose adjustment of concomitant insulin/sulfonylureas may be needed (class effect).

  • Oral medications with narrow therapeutic index

    GLP-1R agonists can delay gastric emptying, potentially affecting absorption kinetics of oral medications. Clinical significance not yet established for survodutide specifically.

  • Other GLP-1 receptor agonists

    Concurrent use not studied and not recommended due to overlapping mechanism and potential for additive GI adverse effects.

  • Warfarin and oral anticoagulants

    No specific data available; delayed gastric emptying from GLP-1R agonism could theoretically affect absorption. INR monitoring recommended as a precaution (class-based consideration).

Research & benefits

Evidence base

Evidence Level
Phase 3
Total Studies
8
Human Participants
7456

Survodutide has completed multiple Phase 1 and Phase 2 trials with approximately 956 participants across four key RCTs (Roux 2024 n=384, Bluher 2023 n=411, Jungnik 2022 n=125, Yazawa 2023 n=36). Phase 3 development includes the SYNCHRONIZE obesity program and the LIVERAGE MASH program. Results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD have been published. All Phase 2 trials demonstrated statistically significant efficacy for weight loss and metabolic improvement with an acceptable safety profile dominated by GI side effects.

Researched for(6)

Rated by confidence in the evidence

  • Significant Weight Loss

    High

    Phase 2 human trial showed about 14.9% weight loss at the highest dose versus 2.8% placebo.

    PMID 38330987 (Lancet Diabetes Endocrinol 2024, le Roux et al., phase 2); PMID 42253238 (le Roux et al., NEJM 2026, phase 3 in adults with obesity).

  • Glycemic Control

    High

    16-week human RCT in type 2 diabetes showed dose-dependent HbA1c reductions versus placebo.

    PMID 38095657 (Diabetologia 2024, Blüher et al.); PMID 40922121 (Diabetes Obes Metab 2025 meta-analysis).

  • MASH/Liver Fat Reduction

    High

    48-week biopsy-confirmed human RCT showed MASH improvement in 62% of patients versus 14% placebo.

    PMID 38847460 (NEJM 2024, Sanyal et al.); PMID 42252333 (SYNCHRONIZE-MASLD, Nat Med 2026).

  • Waist Circumference Reduction

    Medium

    Reduced in phase 2 trials as a secondary measure tracking closely with overall weight loss.

    PMID 39508238 (Diabetol Metab Syndr 2024 meta-analysis); PMID 40922121 (Diabetes Obes Metab 2025 meta-analysis).

  • Dual Mechanism of Action

    Medium

    Dual-receptor pharmacology is confirmed, but added benefit over GLP-1 alone remains unproven.

    PMID 38095657 (Diabetologia 2024, includes open-label semaglutide comparator); NCT05202353 (phase 1 glucagon-receptor study versus semaglutide, active, not recruiting, per ClinicalTrials.gov, October 2026).

  • Potential Cardiovascular Benefits

    Speculative

    No cardiovascular outcome trials have been published, benefit is inferred only from GLP-1 class effects.

    Class extrapolation only. PMID 40922121 (Diabetes Obes Metab 2025 meta-analysis); NCT06077864 (phase 3 cardiovascular safety trial, completed June 2026 per ClinicalTrials.gov, October 2026; no outcome results in the cited literature).

Benefits(6)

  • Significant Weight Loss

  • Glycemic Control

  • MASH/Liver Fat Reduction

  • Waist Circumference Reduction

  • Dual Mechanism of Action

  • Potential Cardiovascular Benefits

Key studies(5)

  1. Roux CW et al.

    The Lancet Diabetes & Endocrinology

    2024

    46-week Phase 2 trial enrolled 387 participants and treated 386. The primary planned-treatment analysis showed 14.9% mean weight loss at the highest assigned dose; the larger 18.7% estimate used an on-treatment analysis.

  2. Sanyal AJ et al.

    New England Journal of Medicine

    2024

    48-week Phase 2 trial in MASH with fibrosis (F1-F3): 62% of 4.8 mg group achieved MASH improvement without fibrosis worsening vs 14% placebo; 67% achieved >=30% liver fat reduction.

  3. Lawitz EJ et al.

    Journal of Hepatology

    2024

    28-week study showed no pharmacokinetic dose adjustment needed for cirrhotic patients; liver fat, stiffness, and volume were generally reduced.

  4. Multiple authors

    Proceedings (Baylor University Medical Center)

    2025

    Meta-analysis of 4 RCTs (n=956): SMD -1.5 for body weight reduction; RR 3.41 for >=5% weight loss, 5.89 for >=10% weight loss; HbA1c reduction -1.12%; higher treatment discontinuation (RR 4.53) but no increased serious AEs.

  5. Multiple authors

    Obesity

    2024

    Design of Phase 3 SYNCHRONIZE-1 (n=726, obesity without T2D) and SYNCHRONIZE-2 (n=755, obesity with T2D) trials evaluating survodutide 3.6 and 6.0 mg weekly doses.

Regulation & availability

Why researchers look at it

In a Phase 2 trial published in the New England Journal of Medicine, 62% of participants in one of the trial's dose groups (not the highest dose) achieved MASH improvement without worsening fibrosis, compared to just 14% on placebo — alongside 18.7% body weight reduction over 46 weeks. Phase 3 development includes the SYNCHRONIZE obesity program and the LIVERAGE MASH program, and phase 3 obesity results have been published. If confirmed, survodutide could become the first dual-agonist approved for fatty liver disease. Approved treatment already exists for selected patients with MASH and fibrosis.

Estimated cost
Not yet available — Phase 3 trials ongoing (Boehringer Ingelheim)
FDA status
Investigational — Not FDA Approved. Key regulatory designations: (1) FDA Breakthrough Therapy Designation for non-cirrhotic MASH with moderate-to-advanced fibrosis (September 2024); (2) FDA Fast Track Designation for non-cirrhotic MASH with moderate-to-advanced liver fibrosis; (3) EU PRIME (Priority Medicines) status for MASH with fibrosis; (4) China Breakthrough Therapy designation for MASH with fibrosis. Phase 3 trials are ongoing with potential NDA submission estimated for 2027-2028 depending on trial results. Developed by Boehringer Ingelheim in partnership with Zealand Pharma.
WADA status
Prohibited at all times under WADA S0 while survodutide has no governmental approval for human therapeutic use. Being unnamed does not exempt an investigational drug. Glucagon is not listed as an S2-prohibited substance.
Prescribability
Not approved — Investigational. FDA Breakthrough Therapy designation granted for MASH (September 2024). Phase 3 clinical trials ongoing (SYNCHRONIZE and LIVERAGE programs). Not available by prescription.
Availability
Not commercially available. Survodutide is an investigational compound available only through enrollment in clinical trials (SYNCHRONIZE and LIVERAGE programs). It is not approved for marketing by any regulatory authority worldwide.

International status

  • US

    Phase 3 trials (Boehringer Ingelheim)

  • Worldwide

    Investigational — not yet approved anywhere

Regulatory timeline(10)

  1. 2020
    Phase 1 clinical trials initiated (healthy volunteers, dose-finding studies)
  2. 2022
    Phase 1b trial results published (Jungnik et al., n=125) demonstrating proof-of-concept for weight loss and metabolic improvements
  3. 2024-02-05
    Phase 2 obesity trial results published (Roux et al., Lancet Diabetes Endocrinol) showing 18.7% weight loss at 4.8 mg dose
  4. 2023
    Phase 2 trial in obesity with T2D published (Bluher et al.) showing up to 8.7% weight loss and 1.71% HbA1c reduction
  5. June 2024
    Phase 2 MASH trial results published in NEJM (Sanyal et al.) — 62% MASH improvement at 4.8 mg; described as dramatic results
  6. September 2024
    FDA Breakthrough Therapy Designation granted for non-cirrhotic MASH with moderate-to-advanced fibrosis
  7. 2024
    EU PRIME status and China Breakthrough Therapy designation received; FDA Fast Track Designation for MASH had already been announced in June 2021.
  8. 2023
    Phase 3 SYNCHRONIZE program launched: SYNCHRONIZE-1 (n=726, obesity), SYNCHRONIZE-2 (n=755, obesity+T2D), SYNCHRONIZE-CVOT (n~5000, CV outcomes)
  9. 2024-2025
    Phase 3 LIVERAGE program launched: LIVERAGE (n~1800, MASH F2-F3) and LIVERAGE-Cirrhosis (n~1590, compensated cirrhosis)
  10. 2027-2028 (estimated)
    Potential NDA/MAA submission depending on Phase 3 trial results and completion timelines

Sources & FAQs

Research sources(10)

  1. PubMed: le Roux CW et al. Lancet Diabetes Endocrinol. 2024 — Phase 2 obesity trial (PMID: 38330987)
  2. PubMed: Sanyal AJ et al. NEJM. 2024 — Phase 2 MASH trial (PMID: 38847460)
  3. PubMed: Lawitz EJ et al. J Hepatol. 2024 — PK/safety in cirrhosis (PMID: 38857788)
  4. PubMed: Systematic review and meta-analysis of survodutide RCTs (PMID: 40922121)
  5. PMC: SYNCHRONIZE-1 and -2 Phase 3 trial design (PMC11664303)
  6. Wikipedia: Survodutide — chemical and pharmacological properties
  7. Boehringer Ingelheim press releases: FDA Breakthrough Therapy designation (Sept 2024)
  8. ClinicalTrials.gov: SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-CVOT, LIVERAGE programs
  9. DrugBank: DB18989 — Survodutide pharmacological profile
  10. Zealand Pharma pipeline page: Survodutide development partnership

Frequently asked questions(5)

How is survodutide different from semaglutide (Ozempic/Wegovy)?

Survodutide is a dual glucagon/GLP-1 receptor agonist, while semaglutide targets only the GLP-1 receptor. The additional glucagon receptor activation may provide extra benefits including increased energy expenditure and enhanced hepatic fat reduction, potentially making survodutide more effective for liver-related conditions like MASH.

When will survodutide be available?

Survodutide is currently in Phase 3 clinical trials. Based on estimated trial completion dates, an FDA submission could occur in 2027-2028 at the earliest. If approved, commercial availability would follow regulatory review, likely no earlier than late 2028.

What are the most common side effects of survodutide?

The most common side effects are gastrointestinal: nausea (RR 3.3x vs placebo), vomiting (RR 6.64x), diarrhea (RR 1.89x), dyspepsia (RR 6.93x), and early satiety (RR 6.44x). These are generally mild, dose-dependent, and consistent with the GLP-1 receptor agonist class. A small increase in heart rate (2.7 bpm) was also observed.

Can survodutide treat fatty liver disease?

Phase 2 results published in the New England Journal of Medicine showed very promising results for MASH (metabolic dysfunction-associated steatohepatitis): up to 62% of patients showed MASH improvement without fibrosis worsening, and up to 67% achieved at least 30% liver fat reduction. Survodutide received FDA Breakthrough Therapy designation for MASH, and Phase 3 LIVERAGE trials are underway.

How much weight can you lose with survodutide?

In Phase 2 clinical trials, participants without type 2 diabetes lost an average of 18.7% of body weight over 46 weeks at the highest dose. Participants with type 2 diabetes lost up to 8.7% over 16 weeks. These results are competitive with or exceed other GLP-1 based treatments, and phase 3 obesity results have since been published.